- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01887431
Telecare in Type 1 Diabetes (T1D) Patients Treated by Insulin Pump
Telecare in Adults With Type 1 Diabetes Mellitus Treated by Insulin Pump - A Randomized Controlled Trial
연구 개요
상세 설명
Objectives
- To evaluate the effect of telecare on glycemic control for patients with type 1 diabetes (T1DM).
- To assess the cost of telecare to Maccabi, the patient and the economy.
- To assess patients' quality of life and satisfaction with telecare intervention.
- To assess the effect of telecare intervention on insulin adjustment to consumed carbohydrates.
- Working hypothesis Telecare can be used for efficient management of T1DM in adults using insulin pump, in lieu of frequent clinic visits.
Methodology A randomized controlled prospective trial for one year. Intervention group: Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
Control group: 3-month routine clinic visits
- Significance of the proposed research (its uniqueness and innovation) Telecare potentially offers a method for efficient continuous care management of patients with T1DM using insulin pump in lieu of clinic visits. It enables real time responses of clinical personnel and increases patient involvement. This trial will be the first telecare intervention lasting for one year to determine if treatment is as efficient as face to face visits, thus enabling cost reduction and time saving without affecting the quality of care. .
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Ra'anana, 이스라엘
- Maccabi Healthcare Services
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients with T1D lasted >1 year, age 22 and up, using insulin pump
- Patients possessing a mobile phone and internet access
Exclusion Criteria:
- Patients with Severe target organ damage
- Patients with Mental retardation
- Patients with Eating disorders
- Pregnant patients or patients planning pregnancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Telecare
Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone.
Frequency of data transfer will be directly related to patients' metabolic control.
|
Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com)
to diabetes team and will receive feedback by telephone.
Frequency of data transfer will be directly related to patients' metabolic control.
In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
|
활성 비교기: Conventional therapy
3-month routine clinic visits
|
3-month routine clinic visits
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Change in Glycosylated Hemoglobin (Hba1c)
기간: From date of randomization every 3 months, up to one year
|
From date of randomization every 3 months, up to one year
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Time spent on data analysis and telephone calls by team
기간: 1 year
|
1 year
|
Number of severe hypoglycemic and diabetic ketoacidosis (DKA) events and hospitalizations
기간: 1 year
|
1 year
|
Patients' quality of life
기간: 1 year
|
1 year
|
Patients' satisfaction
기간: 1 year
|
1 year
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
1형 당뇨병에 대한 임상 시험
-
Rhythm Pharmaceuticals, Inc.완전한Pro-opiomelanocortin(POMC), Proprotein Convertase Subtilisin/Kexin Type 1(PCSK1) 및 Leptin 수용체(LepR) 유전자 돌연변이미국, 이스라엘, 캐나다, 독일, 그리스, 이탈리아, 포르투갈